Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients

NCT07248280 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

260

Enrollment

OTHER

Sponsor class

Conditions

Nausea and Vomiting, Postoperative
Prevention

Interventions

DRUG: Aprepitant 40mg
DRUG: Placebo

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)